Defibrotide is an investigational agent proposed for the treatment of patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome
(SOS), with evidence of multi-organ dysfunction (MOD) following hematopoietic stem-cell transplantation (HSCT).
About VOD VOD, also known as sinusoidal obstruction syndrome
(SOS), is a complication in patients undergoing HSCT therapy.
Of note are the similarities between clinical findings in patients with DENV infection and sinusoidal obstruction syndrome such as hepatomegaly, ascites, right pleural effusion, swelling of the gall bladder wall, and decreased velocity or reversed direction of portal blood flow (10).
Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome.
Patients with alcoholic hepatitis (23) and sinusoidal obstruction syndrome (24) occurring in the setting of severe cellular rejection post liver transplant can have similar lesions and can also have noncirrhotic portal hypertension.
Acute cellular rejection resulting in sinusoidal obstruction syndrome and ascites post-liver transplantation.
Individualized therapeutic drug monitoring must be performed to ensure that busulfan concentrations are optimal for treatment and to reduce the risk for graft rejection, disease relapse, and sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive disease.
Overexposure to the drug produces toxic effects, including sinusoidal obstruction syndrome and gastrointestinal mucositis.
Infections, drug toxicity, the sinusoidal obstruction syndrome
(SOS) and acute graft-versus-host disease (aGVHD) are the most frequent causes of liver abnormalities in the early post-transplant period.
Hepatic sinusoidal obstruction syndrome
(SOS), a serious complication that can occur following either allogeneic or autologous hematopoietic stem cell transplantation (HSCT), was described by Tracy Krimmel, MSN, AOCN[R], APRN-BC, and Loretta A.
Because the sinusoidal lesions were similar to those seen in veno-occlusive disease, also termed sinusoidal obstruction syndrome
, the authors gave the name of sinusoidal obstruction syndrome
(SOS) to these vascular lesions.
AMEX:GNT) (the "Company") today reported that an independent study of Defibrotide was the subject of a published paper titled "Successful Treatment with Defibrotide for Sinusoidal Obstruction Syndrome
(also known as Veno-Occlusive Disease or "VOD") after Hematopoietic Stem Cell Transplantation (SCT)," which appeared in the December 2005 issue of Kobe Journal of Medical Science.